# R1 Therapeutics

> A clinical-stage biopharmaceutical company developing first-in-class therapeutics for chronic kidney disease, led by AP306, a pan phosphate transporter inhibitor for hyperphosphatemia.

R1 Therapeutics is focused on advancing transformative therapies for chronic kidney disease. Its lead programme, AP306, is a first-in-class pan phosphate transporter inhibitor (targeting NaPi-IIb, PiT-1, and PiT-2) in development as a monotherapy for hyperphosphatemia in patients with chronic kidney disease on dialysis. The company is headquartered in Boston, Massachusetts.

## Pages

- [Home](/): Overview of R1 Therapeutics, AP306, and the mission to transform kidney care.
- [Our People](/about/people): Leadership team, board members, and key personnel.
- [Our Story](/about/story): Company history and the origin of the R1 name.
- [Our Partners](/about/partners): Strategic partners and investors, including Alebund Pharmaceuticals.
- [Science](/science): AP306 mechanism of action, hyperphosphatemia disease background, and Phase 2a clinical data.
- [Pipeline](/science/pipeline): Clinical development timeline for AP306 from preclinical through registration.
- [Press Releases](/newsroom/press-releases): Company news and announcements.
- [In the News](/newsroom/in-the-news): External media coverage and publications.
- [Events](/newsroom/events): Upcoming and past conferences and events.
- [Careers](/careers): Current job opportunities at R1 Therapeutics.
- [Contact](/contact): Office locations and enquiry information.
- [Privacy Policy](/privacy-policy): Data privacy and GDPR-compliant analytics practices.
- [Terms of Use](/terms-of-use): Website terms and conditions.

## Optional

- [Press Release](/newsroom/press-releases/:slug): Individual press release articles.